Both in Pharmaceuticals
Neurogene vs PUMA BIOTECHNOLOGY
Over the past year NGNE returned −13.6% and PBYI returned +113.5%; their daily moves had a correlation of 0.01.
NGNE −13.6% PBYI +113.5%Growth of $1, one year, split-adjusted
| Metric | NGNE | PBYI |
|---|---|---|
| Price | $26.85 | $10.76 |
| Market cap | $537.3M | $555.4M |
| Today | +0.67% | +5.28% |
| 1 month | +5.5% | +13.3% |
| 6 months | −17.0% | +44.4% |
| Year to date | +30.3% | +80.8% |
| 1 year | −13.6% | +113.5% |
| Revenue growth (YoY) | — | +7.8% |
| Gross margin | — | 77.9% |
| Net margin | — | 14.5% |
| P/E (TTM) | — | 20.8× |
| Price / sales | — | 2.4× |
| Net cash | $225.4M | $93.9M |
| Dividend yield | — | — |
| Volatility (60d) | 76.3% | 40.8% |
| Short % of float | 39.6% | 11.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).